These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 27580907)

  • 1. Immunomodulatory treatments and cognition in MS.
    Mückschel M; Beste C; Ziemssen T
    Acta Neurol Scand; 2016 Sep; 134 Suppl 200():55-9. PubMed ID: 27580907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive dysfunction in multiple sclerosis: the effect of pharmacological interventions.
    Lyros E; Messinis L; Papageorgiou SG; Papathanasopoulos P
    Int Rev Psychiatry; 2010; 22(1):35-42. PubMed ID: 20222786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis.
    Johnen A; Elpers C; Riepl E; Landmeyer NC; Krämer J; Polzer P; Lohmann H; Omran H; Wiendl H; Göbel K; Meuth SG
    Eur J Paediatr Neurol; 2019 Nov; 23(6):783-791. PubMed ID: 31540711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive deficits including executive functioning in relation to clinical parameters in paediatric MS patients.
    Wuerfel E; Weddige A; Hagmayer Y; Jacob R; Wedekind L; Stark W; Gärtner J
    PLoS One; 2018; 13(3):e0194873. PubMed ID: 29566099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
    Chan D; Binks S; Nicholas JM; Frost C; Cardoso MJ; Ourselin S; Wilkie D; Nicholas R; Chataway J
    Lancet Neurol; 2017 Aug; 16(8):591-600. PubMed ID: 28600189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.
    Chen MH; Goverover Y; Genova HM; DeLuca J
    CNS Drugs; 2020 Jun; 34(6):599-628. PubMed ID: 32361940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery.
    Cinar BP; Kösehasanoğulları G; Yigit P; Ozakbas S
    Neurol Sci; 2017 Feb; 38(2):337-342. PubMed ID: 27885448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cognitive impairment in patients with multiple sclerosis.
    Patti F
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1679-99. PubMed ID: 22876911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive impairment in MS: rehabilitation approaches.
    Hämäläinen P; Rosti-Otajärvi E
    Acta Neurol Scand; 2016 Sep; 134 Suppl 200():8-13. PubMed ID: 27580900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis.
    Miller E; Morel A; Redlicka J; Miller I; Saluk J
    Curr Neuropharmacol; 2018; 16(4):475-483. PubMed ID: 29119933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current advances in the pharmacological prevention and management of cognitive dysfunction in multiple sclerosis.
    Bellinvia A; Portaccio E; Amato MP
    Expert Opin Pharmacother; 2023 Mar; 24(4):435-451. PubMed ID: 36542754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive impairment in multiple sclerosis.
    Jongen PJ; Ter Horst AT; Brands AM
    Minerva Med; 2012 Apr; 103(2):73-96. PubMed ID: 22513513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis.
    Comi G
    Neurol Sci; 2010 Nov; 31(Suppl 2):S261-4. PubMed ID: 20967477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cognitive Impairment in Multiple Sclerosis].
    Niino M; Miyazaki Y
    Brain Nerve; 2020 May; 72(5):509-515. PubMed ID: 32381748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.
    Roy S; Benedict RH; Drake AS; Weinstock-Guttman B
    CNS Drugs; 2016 Mar; 30(3):209-25. PubMed ID: 26884145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective memory in multiple sclerosis: The impact of cue distinctiveness and executive functioning.
    Dagenais E; Rouleau I; Tremblay A; Demers M; Roger É; Jobin C; Duquette P
    Brain Cogn; 2016 Nov; 109():66-74. PubMed ID: 27643953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The weekly calendar planning activity in multiple sclerosis: A top-down assessment of executive functions.
    Goverover Y; Toglia J; DeLuca J
    Neuropsychol Rehabil; 2020 Aug; 30(7):1372-1387. PubMed ID: 30810484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Methodological issues of cognitive impairment studies in pediatric multiple sclerosis patients].
    Bogdanova MD; Mikadze YV; Bembeeva RT; Volkova EY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(9):105-111. PubMed ID: 31626226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric Multiple Sclerosis and Cognition: A Review of Clinical, Neuropsychologic, and Neuroradiologic Features.
    Ekmekci O
    Behav Neurol; 2017; 2017():1463570. PubMed ID: 29434433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Social Cognition Abilities in Patients With Different Multiple Sclerosis Subtypes.
    Henry A; Tourbah A; Chaunu MP; Bakchine S; Montreuil M
    J Int Neuropsychol Soc; 2017 Sep; 23(8):653-664. PubMed ID: 28656885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.